MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/13524585231205962

Медицинская библиотека · Multiple sclerosis (Houndmills, Basingstoke, England) · 2023

Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study.

Brochet Bruno, Solari Alessandra, Lechner-Scott Jeannette, Piehl Fredrik, Langdon Dawn, Hupperts Raymond, Selmaj Krzysztof, Patti Francesco, Brieva Luis, Maida Eva Maria, Alexandri Nektaria, Smyk Andrzej, Nolting Axel, Keller Birgit, Montalban Xavier, Kubala Havrdova Eva

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Multiple sclerosis (MS) negatively affects health-related quality of life (HRQoL).

OBJECTIVE

To evaluate HRQoL in people with highly active relapsing MS treated with cladribine tablets (CladT; 3.5 mg/kg cumulative dose over 2 years) in CLARIFY-MS.

METHODS

Changes in the MS quality of life (MSQoL)-54 scores were analysed using a repeated mixed-effects linear model. Subgroup analyses were performed for participants who were pretreatment-naïve and those pretreated with disease-modifying therapies (DMTs) before initiating CladT. Safety and tolerability of CladT were also assessed.

RESULTS

MSQoL-54 physical (mean change = 4.86; 95% confidence interval (CI) = 3.18, 6.53) and mental health (4.80; 95% CI = 3.13, 6.46) composite scores (primary endpoints) showed significant improvement at Month 24 versus Baseline (p < 0.0001). Changes in the MSQoL-54 scores were consistent across the pretreatment-naïve and DMT-pretreated subgroups. No new severe or opportunistic infections occurred. Most post-baseline lymphopenia events were Grade 1-2 in severity. Transient Grade-3 lymphopenia was observed in 19.7% (95/482) of participants. Grade-4 lymphopenia was not observed.

CONCLUSIONS

CladT treatment significantly improved the mean MSQoL-54 physical and mental health composite scores over 2 years. CladT efficacy in HRQoL, relapse rates and Expanded Disability Status Scale scores demonstrates its multidimensional effects in MS treatment.

Для цитирования: Brochet Bruno, Solari Alessandra, Lechner-Scott Jeannette, Piehl Fredrik, Langdon Dawn, Hupperts Raymond, Selmaj Krzysztof, Patti Francesco, Brieva Luis, Maida Eva Maria, Alexandri Nektaria, Smyk Andrzej, Nolting Axel, Keller Birgit, Montalban Xavier, Kubala Havrdova Eva. Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study.. Multiple sclerosis (Houndmills, Basingstoke, England). 2023. DOI: 10.1177/13524585231205962.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.